BMS-813160

DB16240InvestigationalSmall molecule

BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).

Mechanism: Pharmacologically active on C-C chemokine receptor type 5 and C-C chemokine receptor type 2
Curator reviewed
Formula / weight: C₂₅H₄₀N₈O₂ · 484.649 g/mol (avg)
Code names: BMS-813160

Resolves to

Compound

UNII83U7957287CAS1286279-29-5

Structure

InChIKeyCMVHFGNTABZQJU-HCXYKTFWSA-NSMILESCC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](NC2=NC=NC3=CC(=NN23)C(C)(C)C)C1=O)NC(C)(C)C

Targets

P51681CCR5P41597CCR2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with BMS-813160, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account